There could be an upside to incorporating AI for the FDA. Using AI to assist in final drug reviews would "represent a chance ...

Orphan drug developers face significant difficulties when navigating market access frameworks in Europe. Could greater use of ...

AI-powered tools are enhancing precision, efficiency, and decision-making in biopharmaceutical development. Recently, Jared ...

(Nasdaq: AZTA) today announced a strategic partnership between GENEWIZ from Azenta Life Sciences, a global provider of multiomics and synthetic solutions services, and Form Bio, a leading artificial ...

Orchestra BioMed's AVIM earns FDA breakthrough designation, sparking investor optimism. Click here to read why OBIO stock is ...

The Trump administration has launched a $500 million project to develop a universal flu vaccine that won't need yearly ...

Whether you’re working in a startup, academic lab, or biopharma R&D team, this eBook offers a window into what’s working now and what’s possible next.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Zevra Therapeutics, Inc. ( NASDAQ: ZVRA) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Nichol Ochsner - Vice President Neil McFarlane - President and Chief Executive Officer LaDuane Clifton ...

First Commercial Sales: Humacyte commenced its commercial launch of Symvess in late February 2025 after the first commercial batch was released by the FDA. The first commercial shipments containing ...

Michael Dong recently discussed sample preparation (SP) techniques for small-molecule drug substances and solid dosage forms.